3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
10
Other neoplasm
4
Breast
4
Head & Neck
3
Tumor-Agnostic
1
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Dermatologic
1
Conditions
Pathologic Complete Response
1
Leukemia, Myeloid, Acute
1
Interventions
Cytarabine
898
Cyclophosphamide
893
fludarabine
517
venetoclax
475
fludarabine phosphate
464
Azacitidine
451
Rituximab
418
Methotrexate
414
Etoposide
319
Filgrastim
299
Busulfan
295
Dexamethasone
284
Vincristine
280
Daunorubicin
279
Peripheral Blood Stem Cell Transplantation
257
Whole-Body Irradiation
240
Mycophenolic Acid
231
Decitabine
228
Granulocyte Colony-Stimulating Factor
225
Tacrolimus
219
Idarubicin
203
Melphalan
201
Imatinib Mesylate
195
Cyclosporine
182
Doxorubicin
176
Radiotherapy
169
Prednisone
161
Mitoxantrone
160
Lenalidomide
159
Mercaptopurine
154
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Sulindac
×
Other hematologic neoplasm
×
Clear all
NCT01843179
2017-02-17
Sulindac for Patients With AML
Massachusetts General Hospital
Phase 2
Withdrawn